TR200002242T2 - 5-(2-İmidazolinilamino)-benzimidazol türevleri, bunların hazırlanması ve metabolik kararlılığı gelişmiş alfa-adrenoseptör agonistleri olarak kullanımları. - Google Patents

5-(2-İmidazolinilamino)-benzimidazol türevleri, bunların hazırlanması ve metabolik kararlılığı gelişmiş alfa-adrenoseptör agonistleri olarak kullanımları.

Info

Publication number
TR200002242T2
TR200002242T2 TR2000/02242T TR200002242T TR200002242T2 TR 200002242 T2 TR200002242 T2 TR 200002242T2 TR 2000/02242 T TR2000/02242 T TR 2000/02242T TR 200002242 T TR200002242 T TR 200002242T TR 200002242 T2 TR200002242 T2 TR 200002242T2
Authority
TR
Turkey
Prior art keywords
alpha
imidazolinylamino
preparation
adrenoceptor agonists
metabolic stability
Prior art date
Application number
TR2000/02242T
Other languages
English (en)
Turkish (tr)
Inventor
Lee Cupps Thomas
Lee Bogdan Sophie
Nikolaides Nicholas
Ann Gilbert Sheri
Gazda Michael
Lee Martin Dobson Roy
Iii Charles Andrew Cruze
Original Assignee
The Procter &Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter &Gamble Company filed Critical The Procter &Gamble Company
Publication of TR200002242T2 publication Critical patent/TR200002242T2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TR2000/02242T 1997-11-24 1998-11-20 5-(2-İmidazolinilamino)-benzimidazol türevleri, bunların hazırlanması ve metabolik kararlılığı gelişmiş alfa-adrenoseptör agonistleri olarak kullanımları. TR200002242T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6676797P 1997-11-24 1997-11-24
US6670097P 1997-11-25 1997-11-25

Publications (1)

Publication Number Publication Date
TR200002242T2 true TR200002242T2 (tr) 2000-11-21

Family

ID=26747058

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02242T TR200002242T2 (tr) 1997-11-24 1998-11-20 5-(2-İmidazolinilamino)-benzimidazol türevleri, bunların hazırlanması ve metabolik kararlılığı gelişmiş alfa-adrenoseptör agonistleri olarak kullanımları.

Country Status (23)

Country Link
US (1) US6486190B1 (xx)
EP (1) EP1037887B1 (xx)
JP (1) JP2001524478A (xx)
KR (1) KR20010032435A (xx)
CN (1) CN1284073A (xx)
AT (1) ATE271048T1 (xx)
BR (1) BR9815017A (xx)
CA (1) CA2311344C (xx)
CO (1) CO4970802A1 (xx)
DE (1) DE69825075T2 (xx)
ES (1) ES2223143T3 (xx)
HU (1) HUP0101469A3 (xx)
IL (1) IL136303A (xx)
IN (1) IN190809B (xx)
NO (1) NO20002655L (xx)
NZ (1) NZ504707A (xx)
PE (1) PE133699A1 (xx)
PL (1) PL340711A1 (xx)
RU (1) RU2193562C2 (xx)
SK (1) SK7792000A3 (xx)
TR (1) TR200002242T2 (xx)
TW (1) TW505642B (xx)
WO (1) WO1999026942A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1767525A1 (en) 2001-04-09 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
US20040167194A1 (en) 2003-02-20 2004-08-26 Randall Jared Lynn Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form
CN100366603C (zh) * 2003-02-20 2008-02-06 隆萨股份公司 N-取代甲酰胺的制备方法
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
EP2481412B1 (en) * 2004-05-25 2017-09-27 Galderma Pharma S.A. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
CA2628570A1 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
CA2865593A1 (en) * 2012-02-27 2013-09-06 Eye Therapies Llc Compositions and methods for the treatment of migraine
US20150133516A1 (en) 2013-11-13 2015-05-14 Brian K. Adams Methods and Compositions for Treating ADHD
KR20180105129A (ko) * 2015-11-30 2018-09-27 노부스 테라퓨틱스, 인크. 이과학적 예방 및 치료를 위한 조성물 및 방법
EA030197B1 (ru) * 2016-03-22 2018-07-31 Общество С Ограниченной Ответственностью "Рубикон" Таблетированная форма противовирусного лекарственного средства
JP7163014B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 感冒薬

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4036976A (en) 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
US4217356A (en) 1975-08-22 1980-08-12 Sandoz Ltd. 2-Imidazolinylamino-2,1,3-benzothiadiazoles
US4398028A (en) 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
DE3071229D1 (en) 1979-08-23 1985-12-19 Beecham Group Plc Anti-diarrhoea veterinary composition
US4436913A (en) 1980-09-05 1984-03-13 Siegfried Aktiengesellschaft 1H- and 2H- indazole derivatives
FR2638356A1 (fr) 1988-10-28 1990-05-04 Anben Nouveaux derives de la 2-arylimino-imidazolidine pour diminuer la pression intra-oculaire et traiter le glaucome
US5281591A (en) 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5180721A (en) 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5231096A (en) 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5478858A (en) 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
AU704972B2 (en) 1994-08-04 1999-05-13 H. Lundbeck A/S Novel benzimidazole derivatives
ID24081A (id) * 1997-04-15 2000-07-06 Procter & Gamble Senyawa-senyawa 5-(2-imidazolinilamino) benzimidazol yang berguna sebagai agonis-agonis alfa-2-adrenoseptor

Also Published As

Publication number Publication date
EP1037887A1 (en) 2000-09-27
NZ504707A (en) 2002-11-26
WO1999026942A8 (en) 2000-08-03
HUP0101469A3 (en) 2003-01-28
DE69825075D1 (de) 2004-08-19
IL136303A (en) 2004-02-08
HUP0101469A2 (hu) 2001-10-28
NO20002655L (no) 2000-07-24
RU2193562C2 (ru) 2002-11-27
NO20002655D0 (no) 2000-05-24
ES2223143T3 (es) 2005-02-16
JP2001524478A (ja) 2001-12-04
SK7792000A3 (en) 2001-01-18
TW505642B (en) 2002-10-11
PL340711A1 (en) 2001-02-26
BR9815017A (pt) 2001-09-11
ATE271048T1 (de) 2004-07-15
IN190809B (xx) 2003-08-23
US6486190B1 (en) 2002-11-26
PE133699A1 (es) 2000-03-05
EP1037887B1 (en) 2004-07-14
CA2311344C (en) 2006-02-07
CA2311344A1 (en) 1999-06-03
IL136303A0 (en) 2001-05-20
CN1284073A (zh) 2001-02-14
WO1999026942A1 (en) 1999-06-03
CO4970802A1 (es) 2000-11-07
KR20010032435A (ko) 2001-04-25
DE69825075T2 (de) 2005-08-25

Similar Documents

Publication Publication Date Title
TR200002242T2 (tr) 5-(2-İmidazolinilamino)-benzimidazol türevleri, bunların hazırlanması ve metabolik kararlılığı gelişmiş alfa-adrenoseptör agonistleri olarak kullanımları.
DE602005014341D1 (de) Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken
TR200200588T2 (tr) N-pirazol A2A reseptör agonistleri
TR200401735T4 (tr) Giraz önleyicileri ve bunların kullanımları
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
CR10167A (es) "uso de derivados de sulfamida heterociclica benzo-fusionada para el tratamiento de dolor"
CY1112377T1 (el) Μεθοδος και συνθεσεις για τη θεραπευτικη aντιμετωπιση των αιματολογικων κακοηθειων
BRPI0515488A (pt) derivados de heterocìclicos e seu uso como agentes terapêuticos
AR029605A1 (es) DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
TR199801350T2 (xx) Yeni sikloalkil ikameli imidazoller.
HUP0001358A2 (hu) QT diszperzió és szívverés változékonyság javítása CRF antagonista hatású heterociklusos vegyületek alkalmazásával hirtelen halál megelőzése céljából
BR0113643A (pt) Compostos de guanidinobenzamidas como agonistas de mc4-r e seus usos
TNSN02021A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
EA200100315A1 (ru) Простые тетрагидропиридовые эфиры
ATE366602T1 (de) Festförmiges färbemittel für keratinfasern
DE69928226T8 (de) Chemokin rezeptor antagonisten und verwendung
MA39043B1 (fr) Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs
TR199903277T2 (xx) Benzimidazol t�revleri.
IS6426A (is) Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni
PT1165065E (pt) Comprimidos para degluticao com elevada concentracao de n-acetilcisteina
DE3673835D1 (de) Dopamin-beta-hydroxylase-inhibitoren.
PE20021153A1 (es) 5-[2-BUTOXI-5-(1-HIDROXIETIL)-3-PIRIDINIL]-3-ETIL-2-(1-ETIL-3-AZETIDINIL)-2,6-DIHIDRO-7H-PIRAZOLO[4,3-d]PIRIMIDIN-7-ONA COMO INHIBIDORES DE FOSFODIESTERASAS DE GUANOSIN 3',5'-MONOFOSFATO CICLICO
ATE217531T1 (de) Verwendung von natriumchlorid zur verminderung der gastrointestinalen toxizität von camptotecinderivaten.
TR199802033T2 (xx) Böcek öldürücü siprodinil ve miklobutanil bileşimi.
UA94055C2 (xx) Заміщені бензімідазоли як інгібітори кіназ[замещеные бензимидазолы в качестве ингибиторов киназ